Mr Harith Akram FRCS (Neuro.Surg) Ltd 13472312 false 2022-07-01 2023-06-30 2023-06-30 The principal activity of the company is that of specialists medical practice activities. Digita Accounts Production Advanced 6.30.9574.0 true 13472312 2022-07-01 2023-06-30 13472312 2023-06-30 13472312 bus:OrdinaryShareClass1 2023-06-30 13472312 core:CurrentFinancialInstruments 2023-06-30 13472312 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 13472312 core:FurnitureFittingsToolsEquipment 2023-06-30 13472312 bus:SmallEntities 2022-07-01 2023-06-30 13472312 bus:AuditExemptWithAccountantsReport 2022-07-01 2023-06-30 13472312 bus:FullAccounts 2022-07-01 2023-06-30 13472312 bus:SmallCompaniesRegimeForAccounts 2022-07-01 2023-06-30 13472312 bus:RegisteredOffice 2022-07-01 2023-06-30 13472312 bus:Director1 2022-07-01 2023-06-30 13472312 bus:Director2 2022-07-01 2023-06-30 13472312 bus:OrdinaryShareClass1 2022-07-01 2023-06-30 13472312 bus:PrivateLimitedCompanyLtd 2022-07-01 2023-06-30 13472312 core:FurnitureFittingsToolsEquipment 2022-07-01 2023-06-30 13472312 countries:EnglandWales 2022-07-01 2023-06-30 13472312 2021-06-23 2022-06-30 13472312 2022-06-30 13472312 bus:OrdinaryShareClass1 2022-06-30 13472312 core:CurrentFinancialInstruments 2022-06-30 13472312 core:CurrentFinancialInstruments core:WithinOneYear 2022-06-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 13472312

Mr Harith Akram FRCS (Neuro.Surg) Ltd

Unaudited Filleted Financial Statements

for the Year Ended 30 June 2023

 

Mr Harith Akram FRCS (Neuro.Surg) Ltd

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 7

 

Mr Harith Akram FRCS (Neuro.Surg) Ltd

Company Information

Directors

Dr Harith Akram

Mrs Rebecca Akram

Registered office

178 Weir Road
London
SW12 0NP

Accountants

Aventus Partners Limited
Hygeia Building
Ground Floor
66-68 College Road
Harrow
Middlesex
HA1 1BE

 

Mr Harith Akram FRCS (Neuro.Surg) Ltd

(Registration number: 13472312)
Balance Sheet as at 30 June 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

970

-

Current assets

 

Debtors

5

66

3,897

Cash at bank and in hand

 

18,880

5,690

 

18,946

9,587

Creditors: Amounts falling due within one year

6

(9,077)

(8,187)

Net current assets

 

9,869

1,400

Net assets

 

10,839

1,400

Capital and reserves

 

Called up share capital

7

100

100

Retained earnings

10,739

1,300

Shareholders' funds

 

10,839

1,400

For the financial year ending 30 June 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

These financial statements were approved and authorised for issue by the Board on 4 March 2024 and signed on its behalf by:
 

.........................................
Dr Harith Akram
Director

 

Mr Harith Akram FRCS (Neuro.Surg) Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
178 Weir Road
London
SW12 0NP
United Kingdom

These financial statements were authorised for issue by the Board on 4 March 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The functional and presentational currency is GBP Sterling (£), being the currency of the primary economic environment in which the company operates in. The amounts are presented rounded to the nearest pound.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of income, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Mr Harith Akram FRCS (Neuro.Surg) Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2023 (continued)

2

Accounting policies (continued)

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

25% Reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Mr Harith Akram FRCS (Neuro.Surg) Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2023 (continued)

2

Accounting policies (continued)

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Financial instruments

Classification
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans from related parties.

 Recognition and measurement
Debt instruments (other than those wholly repayable or receivable within one year), including loans and other debtors and creditors, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method.

Debt instruments that are payable or receivable within one year, typically trade creditors or debtors, are
measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms of financed at a rate of interest that is not a market rate or in case of an out-right short term loan not at a market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.


 Impairment
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss if recognised in the Profit and loss account.

For financial assets measured as amortised cost, the impairment loss is measured as the difference between an asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate. If a financial asset has a variable interest rate, the discounted rate for measuring any impairment loss is the current effective interest rate determined under the contract.

Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3

Staff numbers

The average monthly number of persons employed by the company (including directors) during the year, was 2 (2022: 2).

 

Mr Harith Akram FRCS (Neuro.Surg) Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2023 (continued)

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost

Additions

1,293

1,293

At 30 June 2023

1,293

1,293

Depreciation

Charge for the year

323

323

At 30 June 2023

323

323

Carrying amount

At 30 June 2023

970

970

5

Debtors

2023
£

2022
£

Prepayments

66

3,897

66

3,897

6

Creditors

Creditors: amounts falling due within one year

Note

2023
£

2022
£

Due within one year

 

Accrued expenses

 

1,080

1,080

Corporation tax payable

 

2,381

922

Directors current account

 

5,616

6,185

 

9,077

8,187

 

Mr Harith Akram FRCS (Neuro.Surg) Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2023 (continued)

7

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary shares of £1 each

100

100

100

100

         

8

Dividends

   

2023

 

2022

   

£

 

£

Interim dividend of £20.00 (2022 - £30.00) per ordinary share

 

2,000

 

3,000